Research hub · 8 articles
Peptide Regulation & 503A
Regulation is the part of peptide supply that changes faster than the chemistry. The same molecule can be a lawful compounding ingredient in one jurisdiction, an unapproved drug in a second, and a scheduled substance in a third, and the status can shift on the publication of a single list. For a laboratory buyer, that means the paperwork around a compound is as much a part of its identity as the certificate of analysis.
The articles in this cluster trace the mechanics rather than the politics. One explains what section 503A of the Food, Drug and Cosmetic Act allows a licensed compounding pharmacy to do with bulk substances, and why the FDA's bulk-substance category lists matter more than any individual enforcement action. Another follows the sequence of import alerts and market withdrawals that reshaped research-peptide availability through 2025 and into 2026. A third walks through a certificate of analysis in detail, because the COA is where regulatory claims and analytical reality meet, and the two often diverge. Read them together: the timeline makes more sense once the 503A framework is clear, and the COA piece explains what documentation survives a compliance question.
Dates matter here more than in any other hub. The timeline piece is written to be read against its publication date, and an alert that was current in mid-2026 may have been superseded by the time you read it. Where a page states a regulatory fact it names the instrument — a bulk-substance list, an import alert, a guidance document — so the claim can be re-checked at the source rather than taken on our authority.
Articles in this hub
FDA PCAC 2026: Six Peptides for 503A Compounding
The July 2026 PCAC vote recommending BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax for the 503A Bulks List — the regulatory update researchers should know.
9 Aug 2026
The Peptide Cliff: 503A Expansion and Supply
Why compounded semaglutide ended in 2025, what the July 2026 FDA 503A expansion changes, and how the regulatory shake-up reshapes the research peptide supply.
15 Aug 2026
The 2026 Peptide Regulatory Timeline
Month by month through 2026: the April removal of 12 peptides from the 503A Category 2 list, the July PCAC votes with exact tallies, and the pending reviews — a working tracker for research buyers.
10 Sept 2026
Importing Research Peptides: Documents, Alerts and Holds
What actually decides an import: entry data, import alerts and DWPE, recall history, and how to verify a supplier's claims against FDA's own records. Not legal advice.
16 Nov 2026
The 2025-2026 US Peptide Market Collapse
Nine+ US research-peptide vendors shut down between late 2025 and mid-2026 — Peptide Sciences overnight, Paradigm's founder to federal prison. The three enforcement forces behind the collapse, and the verifiable-COA standard that now separates survivors from the next casualty list.
10 Sept 2026
BPC-157 and the 503A Bulks List: July 2026
BPC-157 was recommended for the FDA 503A Bulks List in July 2026 — what the vote means, what it doesn't change, and the research status of the pentadecapeptide.
15 Aug 2026
How to Read a Peptide COA: A Field Guide for Researchers
Every block on a peptide certificate of analysis, what each assay actually measures, and the eight checks that separate a usable COA from a decorative one — with a worked example.
10 Sept 2026
Choosing a Research Peptide Supplier: Nine Checks
A buyer-side evaluation framework for peptide and analytical-steroid vendors — COA linkage, batch consistency, CAS discipline, cold-chain reality, and the red flags that correlate with mislabeled product.
10 Sept 2026
Related categories
Related tools
More hubs and compound references in the research journal; analytical documentation on the quality page; or request a quote.